The biomedicine industry of Guangzhou's Huangpu district recorded operating revenue of 39.61 billion yuan ($6.1 billion) in the first quarter of this year, up 25.5 percent year-on-year.
As of now, the district is home to more than 3,000 biomedical enterprises, the output value of which accounts for more than 60 percent of the city's total. It has eight provincial high-level innovation research institutes, or two thirds of Guangdong's total.
In addition, Huangpu has gathered more than 700 high-end life science talents, as well as over 40 academicians including Zhong Nanshan, Xu Tao and Shi Yigong. It has fostered a development pattern centered on two cities and one island.
Guangzhou Science City focuses on pilot scale tests and incubation, and will become a global top-tier biomedical scientific and technological achievement transformation center.
China-Singapore Guangzhou Knowledge City is envisioned as an aggregated zone for leading biomedical enterprises and a first-class world-level life science R&D collaboration demonstration area. It has gathered a number of heavyweight projects invested by GE Healthcare, Lonza, and BeiGene.
A national biomedical incubator, Guangzhou International Bio Island has brought in more than 510 biomedical enterprises and many high-end new-type R&D platforms such as Guangzhou Regenerative Medicine and Health Guangdong Laboratory (Bioland Laboratory). It will become a world leading biomedical and biosafety R&D center and a national pilot zone for biomedical policy innovation.